Rodolphe Barrangou
From Wikipedia, the free encyclopedia
Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University; Co-Founder and Chief Executive Officer of CRISPR Biotechnologies; Co-Founder and Chief Scientific Officer of Ancilia Biosciences; Co-Founder, President and Chief Scientific Officer of TreeCo; and Co-Founder and member of the Scientific Advisory Board of Intellia Therapeutics. His research focuses on CRISPR-Cas9 in bacteria.[1]
Rodolphe Barrangou | |
---|---|
Alma mater | |
Scientific career | |
Institutions | |
In 2017, Barrangou was named[2] Editor-in-Chief of The CRISPR Journal, a peer-reviewed journal covering the field of genome editing and CRISPR research, which debuted in February 2018.
He was elected as a member into the National Academy of Sciences in 2018.[3] He was also elected into the National Academy of Engineering in 2019 for the discovery of CRISPR-Cas genome editing and engineering microbes, plants, and animals for food and other applications.